Trial intelligence / Profile preview

52-week randomized double-blind placebo-controlled study of GSK1605786A for maintenance of remission in Crohn's disease

2010-022383-12Phase 3Terminated

Sponsor
GSK
Start
Oct 2010
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in Crohn's disease comparing GSK1605786A with Placebo (2 arms). Started Oct 2010; status: terminated.

02

Drugs

vercirnon
03

Conditions

Crohn's disease

Beyond the preview

Go deeper on 2010-022383-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022383-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call